Chemical and biological investigation of N-hydroxy-valdecoxib: An active metabolite of valdecoxib

Bioorganic and Medicinal Chemistry

Volumn 16, Issue 9, 2008, Pages 5322-5330

  Erdélyi, Péter ^a   Fodor, Tamás ^a   Varga, Ágnes Kis ^a   Czugler, Mátyás ^b   Gere, Anikó ^a   Fischer, János ^a  

^a GEDEON RICHTER LTD   (Hungary)

^b CHEMICAL RESEARCH CENTER   (Hungary)

Author keywords

Active metabolite; COX 2; Cyclooxygenase 2 inhibitor; Non steroidal anti inflammatory drugs; Valdecoxib analogues

Indexed keywords

ANTIINFLAMMATORY AGENT; CARRAGEENAN; CYCLOOXYGENASE 2 INHIBITOR; DRUG METABOLITE; N HYDROXY 4 (5 METHYL 3 PHENYLISOXAZOL 4 YL)BENZENESULFONAMIDE; PROSTAGLANDIN SYNTHASE; VALDECOXIB;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CHRONIC PAIN; CONTROLLED STUDY; DRUG STABILITY; DRUG SYNTHESIS; EDEMA; ENZYME INHIBITION; INFLAMMATORY DISEASE; MALE; MOUSE; NONHUMAN; PAIN; RAT;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CARRAGEENAN; CATTLE; CRYSTALLOGRAPHY, X-RAY; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; EDEMA; HUMANS; HYPERALGESIA; INFLAMMATION; ISOXAZOLES; MALE; MODELS, MOLECULAR; MOLECULAR STRUCTURE; PAIN; PAIN MEASUREMENT; RABBITS; RATS; RATS, WISTAR; RECOMBINANT PROTEINS; STEREOISOMERISM; SULFONAMIDES; TIME FACTORS;

EID: 43049174838     PISSN: 09680896     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmc.2008.02.088     Document Type: Article

References (23)

1. Vane J.R. Nature (New Biol.) 231 (1971) 232
2. Raz A., Wyche A., Siegel N., and Needleman P. J. Biol. Chem. 263 (1988) 3022
3. Fu J.R., Masferrer J.L., Seibert K., Raz A., and Needleman P. J. Biol. Chem. 265 (1990) 16737
4. Battistini B., Botting B., and Bakhle Y.S. Drug News Perspect. 7 (1994) 501
5. Xie W., Chipman J.G., Robertson D.L., Erikson R.L., and Simmons D.L. Proc. Natl. Acad. Sci. U.S.A. 88 (1991) 2692
6. Kujubu D.A., Fletcher B.S., Varnum B.C., Lim R.W., and Herschman H.R. J. Biol. Chem. 266 (1991) 12866
7. O'Banion M.K., Sadowski H.B., Winn V., and Young D.A.A. J. Biol. Chem. 266 (1991) 23261
8. Vane J.R., and Botting R.M.. Adv. Prostaglandin, Thromboxane, Leukot. Res. 23 (1995) 41
9. Allison M.C., Howatson A.G., Torrance C.J., Lee F.D., and Russell R.I.G. N. Engl. J. Med. 310 (1984) 563
10. Penning T.D., Talley J.J., Bertenshaw S.R., Carter J.S., Collins P.W., Docter S., Graneto M.J., Lee L.F., Malecha J.W., Miyashiro J.M., Rogers R.S., Rogier D.J., Yu S.S., Anderson G.D., Burton E.G., Cogburn J.N., Gregory S.A., Koboldt C.M., Perkins W.E., Seibert K., Veenhuizen A.W., Zhang Y.Y., and Isakson P.C. J. Med. Chem. 40 (1997) 1347
11. In: Fischer J., and Ganellin C.R. (Eds). Analogue-Based Drug Discovery (2006), Wiley-VHC Verlag GmbH & Co. KGaA
12. Talley J.J., Brown D.L., Carter J.S., Graneto M.J., Koboldt C.M., Masferrer J.L., Perkins W.E., Rogers R.S., Shaffer A.F., Zhang Y.Y., Zweifel B.S., and Seibert K. J. Med. Chem. 43 (2000) 775
13. Uddin Md.J., Rao P.N.P., and Knaus E.E. Bioorg. Med. Chem. 11 (2003) 5273
14. Zarghi A., Rao P.N.P., and Knaus E.E. Bioorg. Med. Chem. 15 (2007) 1056
15. Zhang J.Y., Yuan J.J., Wang Y.F., Bible R.H., and Breau A.P. Drug Metab. Dispos. 31 (2003) 491
16. Yuan J.J., Yang D.C., Zhang J.Y., Bible R., Karim A., and Findlay J.W.A. Drug Metab. Dispos. 30 (2002) 1013
17. Bonner F.T., and Ko Y. Inorg. Chem. 31 (1992) 2514
18. Zamora R., Grzesiok A., Weber H., and Feelisch M. Biochem. J. 312 (1995) 333
19. Gierse K., Hauser S.D., Creely D.P., Koboldt C.M., Rangwala S.H., Isakson P.C., and Siebert K. Biochem. J. 305 (1995) 479
20. In: Vogel H.G., and Vogel W.H. (Eds). Drug Discovery and Evaluation Pharmacological Assays (1997), Springer-Verlag, Berlin, Heidelberg
21. Atkinson D.C. Arch. Int. Pharmacodyn. Ther. 193 (1971) 391
22. ***p < 0.001).
23. Neutral atomic scattering factors and anomalous scattering factors are taken from:. In: Wilson A.J.C. (Ed). International Tables for X-ray Crystallography Vol. C (1992), Kluwer Academic Publishers, Dordrecht Tables 6.1.1.4, pp 500-502, 4.2.6.8, pp 219-222 and 4.2.4.2, pp 193-199